【原美源伯根】Cencora（COR）2024财年年度总结报告「NYSE」（英文版）（116页）.pdf

1、Summary Annual Report202403 About Cencora05 CEO letter13 Financial highlights14 Management team15 Board of Directors16 GAAP/Non-GAAP financial measures18 Corporate informationTable of contents03AboutCencoraCencora is a leading global pharmaceutical solutions organization centered on improving the li

2、ves of people and animals around the world.We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.Care providers depend on us for the secure,reliable delivery of pharmaceuticals,healthcare products,and solutions.04CEO letter05It is an h

3、onor to be the President and CEO of Cencora.Thank you to the Board of Directors for their trust and to Steve Collis for the seamless hand-off and ongoing leadership and partnership as Executive Chairman of the Board.Since assuming the role of President and CEO of Cencora on October 1,2024,I have bee

4、n focused on furthering the strengths that have been key to our past success and investing to ensure we continue to be at the forefront of innovation and advance our ability to leverage data and analytics.We will lead with a customer-centric approach,take on an enterprise-powered mindset and focus o

5、n innovation,which will ensure our differentiated value-proposition remains intact and accelerates our position as a leader in healthcare.We are well positioned with our foundation in pharmaceutical distribution and key commercialization capabilities that allow us to provide differentiated and integ

6、rated solutions.I am confident in the continued success of Cencora and inspired by our team members pride in their work and deep dedication to our purpose We are united in our responsibility to create healthier futures.In fiscal 2024,Cencora delivered robust financial performance while enhancing our